According to Research Study, global glycomics market size is expected to reach around USD 3.5 billion by 2030 and is anticipated to grow at a CAGR of 14.10% during forecast period 2022 to 2030.
According to Research Study, global glycomics market size is expected to reach around USD 3.5 billion by 2030 and is anticipated to grow at a CAGR of 14.10% during forecast period 2022 to 2030.
Report Highlights
- In 2021, instruments held the largest market share owing to frequent usage in drug discovery and diagnostic testing.
- Glycosidases held the largest market share in terms of revenue. The segment is anticipated to witness a CAGR of 18.31% from 2021 to 2030.
- On the basis of end use, academic and research institutes accounted for the largest revenue share in 2021.
- On the basis of application, drug discovery and development accounted for the largest market share in 2021.
- North America accounted for the largest market share in 2021.
- Asia Pacific is expected to be the second fastest-growing regional market during the forecast period.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37072
The increasing number of patients suffering from chronic diseases is anticipated to revive the growth of the global glycomics market. The market is expected to witness abundance of growth opportunities in the upcoming years. The increasing presence of pharmaceutical companies and research institutes to boost the drug discovery and development sector is driving the global glycomics market. Advancements in this field have played a major role in drug investigation during coronavirus pandemic. Technological advancements on biotechnology, investments on R&D activities to study gycans or polysaccharides, and increasing applications in disease diagnostics are creating revenue opportunities amid pandemic in the global market.
Glycomics or Glycobiology is the study of structure, biology, and function of saccharides which are widely distributed in nature and regarded as glycans as well. Glycans are found in all living organisms. Glycobiology is a rapidly progressing biological area of interest for various fields like biotechnology, biomedicine, and basic research. Most proteins are revised after the translation process in eukaryotic cells. The attachment of glycans is one of the most usual modifications for cell viability. There are two forms of glycosylation 1) N-linked glycosylation: when glycan is attached to asparagines 2) O-linked glycosylation: when the glycan is attached to a serine or threonine.
Glycobiology has a vast range of applicability like diagnostics, oncology, drug discovery & development, immunology, and various other applications. Glycomics is a widely emerging scientific field highlighting on defining functional aspects of glycans in biosystems.
Product Insights
In 2021, instruments held the largest market share owing to frequent usage in drug discovery and diagnostic testing. In addition, repetitive purchase of reagents and kits is another major factor expected to boost segment growth. Enzymes are estimated to account for a considerable market share in near future due to rising research in cancer therapeutics and diagnosis.
Glycomics uses various research approaches to quantify or define glycome of a tissue, cell, or organism. Alteration such as localization or in the activity of enzymes involved in glycan biosynthesis ultimately results in changing of the final glycan structure. Therefore, apart from genetic markups of individuals, glycans can be analyzed to assess environmentally induced changes. This study can be used in disease diagnosis and drug discovery. This is one of the major factors propelling segment growth.
A large number of research studies have been conducted to commercialize glycoside inhibitors that are known to alter N-linked glycans of cancer cells and viruses. Therapeutic use of these enzymes include direct antiviral, antibacterial, and anti-cancer activities. They aid in treatment of diseases caused by deficiencies such as Tay-Sachs disease and Gaucher disease, and most importantly, diabetes. Thus, among enzymes, glycosidases held the largest market share in terms of revenue. The segment is anticipated to witness a CAGR of 18.31% from 2021 to 2030.
Various research studies indicate that epigenetic regulation of glycans in cancer cells results in formation of new glycan structures. These structures are one of the mechanisms used by cancerous cells to evade immune response in a host. Scientists have designed genetic engineered cell models to understand functions of specific glycan cancer epitopes. These factors are therefore anticipated to propel market growth during the forecast period.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37072
End Use Insights
On the basis of end use, academic and research institutes accounted for the largest revenue share in 2021 due to increased R&D investments. Collaborations between major organizations and research institutes are further supporting the segment expansion. The pharmaceutical and biotechnology companies segment is anticipated to register the fastest CAGR during the forecast period owing to increasing R&D investments in drug discovery and development and in other glycobiology based studies.
Increasing adoption of glycan structure data analysis by research centers also contributes to the segment growth. Preference for glycomics for training and educational purposes is another factor contributing to the segment growth. A wide range of applications in drug discovery and development, biomedical research, cell biology, immunology, and biochemistry is expected to drive the market in near future.
Application Insights
On the basis of application, drug discovery and development accounted for the largest market share in 2021. This is primarily owing to extensive R&D and increased government funding for research related to glycomics and proteomics. The other applications segment is anticipated to witness the highest CAGR over the forecast period due to rising clinical trials and R&D expenses incurred by key companies for research. For instance, R&D expenditure of Merck accounted for USD 2.4 billion in 2021.
Research in glycome informatics, which helps in identification and analysis of drug targets and biomarkers, is increasing due to wide application of glycan structure analysis in bioinformatics. Glycomics involves study of functions and structures of glycans in biological systems. Thus, it can be used in personalized medicines for early detection of diseases to select suitable line of treatment. Combining glycomics and genomics helps in diagnosis of congenital disorders of glycosylation including CCDC115-CDG, ATP6AP1-CDG, PGM1-CDG, TMEM199-CDG, and MAN1B1-CDG.
Regional Insights
North America accounted for the largest market share in 2021 due to the presence of key pharmaceutical and biopharmaceutical companies including Merck KGaA, Agilent Technologies, Danaher, and Thermo Fisher Scientific. Presence of well-established healthcare infrastructure and accessibility to advanced products have driven the regional market. Moreover, government funding for R&D activities is another key factor boosting the glycobiology market growth in this region.
Asia Pacific is expected to be the second fastest-growing regional market during the forecast period owing to untapped market opportunities. Evolving pharmaceutical and biopharmaceutical industries have resulted in immense growth of glycomics in the region. In addition, investments by Contract Research Organizations (CROs) for the development and production of drugs and biologics are expected to fuel growth of the Asia Pacific glycomics market.
Glycoscience with its significance in modern biotechnology and also its ability to access new and innovative technologies is anticipated to offer bio-based industries in Europe with competitive advantage at a global level. Developments have led to introduction of the European Glycoscience Network (EGSF) to address cross-disciplinary integrated interactions with global glycoscience networks established in U.S.
Latin America is anticipated to witness steady growth owing to rapidly developing economies, presence of leading pharmaceutical companies, and evolving healthcare infrastructure. Brazil is expected to expand at a lucrative CAGR during the forecast period owing to increasing life science-related research and developing healthcare infrastructure.
Key Players
Thermo Fisher Scientific, Inc.; Merck KGaA; Agilent Technologies; Bruker; New England Biolabs; Danaher; Shimadzu Corporation; Takara Bio, Inc.; and ProZyme.
Market Segmentation
- Product Outlook
- Enzymes
- Glycosidases
- Neuraminidases
- Glycosyltransferases
- Sialyltransferases
- Others
- Kits
- Glycan Labeling Kits
- Glycan Purification Kits
- Glycan Release Kits
- Others
- Reagents
- Glycoproteins
- Monosaccharides
- Oligosaccharides
- Others
- Instruments
- Mass Spectrometers
- HPLC
- MALDI-TOF
- Array Systems
- Others
- Enzymes
- Application Outlook
- Drug Discovery & Development
- Diagnostics
- Others
- End Use Outlook
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- CROs
- Regional Outlook
- North America
- Europe
- Latin America
- Asia Pacific
- MEA
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37072
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333